Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

China Metered Dose Inhalers Market

ID: MRFR/HC/48607-HCR
200 Pages
Rahul Gotadki
Last Updated: April 06, 2026

China Metered Dose Inhalers Market Research Report: Size, Share, Trend Analysis By Product (Press Metered Dose Inhalers, Breath Actuated Metered Dose Inhalers), By Propellant Type (HFA 134A, HFA 227EA, HFA 152A), By Technology (Pulmonary Platform Technologies, Nasal Platform Technologies), By Indication (Asthma, COPD, Others) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Growth Outlook & Industry Forecast 2025 To 2035

English
Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Chemicals and Materials, BY Product (USD Million)
      1. 4.1.1 Press Metered Dose Inhalers
      2. 4.1.2 Breath Actuated Metered Dose Inhalers
    2. 4.2 Chemicals and Materials, BY Propellant Type (USD Million)
      1. 4.2.1 HFA 134a
      2. 4.2.2 HFA 227ea
      3. 4.2.3 HFA-152a
    3. 4.3 Chemicals and Materials, BY Technology (USD Million)
      1. 4.3.1 Pulmonary Platform Technologies
      2. 4.3.2 Nasal Platform Technologies
    4. 4.4 Chemicals and Materials, BY Indication (USD Million)
      1. 4.4.1 Asthma
      2. 4.4.2 COPD
      3. 4.4.3 Others
    5. 4.5 Chemicals and Materials, BY Distribution Channel (USD Million)
      1. 4.5.1 Hospital Pharmacies
      2. 4.5.2 Retail Pharmacies
      3. 4.5.3 Online Pharmacies
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 AstraZeneca (GB)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Boehringer Ingelheim (DE)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 GlaxoSmithKline (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Teva Pharmaceutical Industries (IL)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Mylan (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Roche (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Sanofi (FR)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Pfizer (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 CHINA MARKET ANALYSIS BY PRODUCT
    3. 6.3 CHINA MARKET ANALYSIS BY PROPELLANT TYPE
    4. 6.4 CHINA MARKET ANALYSIS BY TECHNOLOGY
    5. 6.5 CHINA MARKET ANALYSIS BY INDICATION
    6. 6.6 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    7. 6.7 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF CHEMICALS AND MATERIALS
    10. 6.10 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    12. 6.12 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
    13. 6.13 CHEMICALS AND MATERIALS, BY PRODUCT, 2024 (% SHARE)
    14. 6.14 CHEMICALS AND MATERIALS, BY PRODUCT, 2024 TO 2035 (USD Million)
    15. 6.15 CHEMICALS AND MATERIALS, BY PROPELLANT TYPE, 2024 (% SHARE)
    16. 6.16 CHEMICALS AND MATERIALS, BY PROPELLANT TYPE, 2024 TO 2035 (USD Million)
    17. 6.17 CHEMICALS AND MATERIALS, BY TECHNOLOGY, 2024 (% SHARE)
    18. 6.18 CHEMICALS AND MATERIALS, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    19. 6.19 CHEMICALS AND MATERIALS, BY INDICATION, 2024 (% SHARE)
    20. 6.20 CHEMICALS AND MATERIALS, BY INDICATION, 2024 TO 2035 (USD Million)
    21. 6.21 CHEMICALS AND MATERIALS, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    22. 6.22 CHEMICALS AND MATERIALS, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY PRODUCT, 2025-2035 (USD Million)
      2. 7.2.2 BY PROPELLANT TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY TECHNOLOGY, 2025-2035 (USD Million)
      4. 7.2.4 BY INDICATION, 2025-2035 (USD Million)
      5. 7.2.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

China Chemicals and Materials Market Segmentation

Chemicals and Materials By Product (USD Million, 2025-2035)

  • Press Metered Dose Inhalers
  • Breath Actuated Metered Dose Inhalers

Chemicals and Materials By Propellant Type (USD Million, 2025-2035)

  • HFA 134a
  • HFA 227ea
  • HFA-152a

Chemicals and Materials By Technology (USD Million, 2025-2035)

  • Pulmonary Platform Technologies
  • Nasal Platform Technologies

Chemicals and Materials By Indication (USD Million, 2025-2035)

  • Asthma
  • COPD
  • Others

Chemicals and Materials By Distribution Channel (USD Million, 2025-2035)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies